13th Sep 2007 09:42
Sareum Holdings PLC13 September 2007 For immediate release 13 September 2007 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Notice of Preliminary Results Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discoverybusiness, will be announcing its preliminary results for the twelve month periodended 30 June 2007 on Tuesday 2 October 2007. An analyst presentation will take place on the day at 10:00am at BuchananCommunications, 45 Moorfields, London EC2Y 9AE. For further information please contact: Sareum Holdings 01223 497700 Tim Mitchell, Chief Executive Officer Buchanan Communications 020 7466 5000 Tim Anderson, Mary-Jane Johnson Grant Thornton Corporate Finance 020 7383 5100 Philip Secrett, Colin Aaronson About Sareum Holdings plc Sareum Holdings plc is a structure-based drug discovery business headquarteredin Cambridge, UK. The Company was formed in August 2003 to discover new drugsfor the treatment of cancer. Sareum's unique approach aims to halve the time ittakes to discover new drug candidates. A structure-based approach to drug discovery relies on knowledge of thethree-dimensional structure of the proteins that cause disease. Once thestructure is known, potential drugs are designed to 'lock-in' to the proteinwith the aim of reversing or arresting a disease's progression. Knowledge ofthe structure of the potential drugs and how they 'lock-in' to their targetprotein assists greatly in the development of high-quality drug candidates.Determining structure is a complex task and requires leading-edge equipment andexperienced staff. Sareum's approach to structure determination utilises itsproprietary protein expression platform in order to produce multiple recombinantproteins that accelerate structure determination using x-ray crystallography. Once the structure is determined, the Company's innovative fragment screeningplatform is used to identify novel chemical templates designed to interact withthe target protein. Sareum then uses its high-throughput medicinal chemistryplatform to rapidly optimise these molecules and develop the most promising intopotential drug candidates. Sareum aims to successfully deliver drug candidates for licensing to largerpharmaceutical companies at the pre-clinical or early clinical trials stage.This is funded by provision of its specialist drug discovery capabilities topartners in the pharmaceutical and biotechnology industries. Sareum joined the AIM market of the London Stock Exchange in October 2004 andtrades under the symbol SAR. For further information, please visit www.sareum.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sareum